<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18690851</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1574-8847</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>2</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2007</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current clinical pharmacology</Title>
          <ISOAbbreviation>Curr Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Warfarin dosing and the promise of pharmacogenomics.</ArticleTitle>
        <Pagination>
          <StartPage>11</StartPage>
          <EndPage>21</EndPage>
          <MedlinePgn>11-21</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Due to its narrow therapeutic index and substantial inter-patient variability in clinical response, warfarin represents an ideal drug candidate to benefit from the promise of pharmacogenomic-guided dosing strategies. Consistent with in vitro data, clinical studies have demonstrated that CYP2C9 polymorphisms significantly influence warfarin pharmacokinetics by reducing (S)-warfarin metabolic clearance, consequently lowering maintenance dose requirements and increasing the risk over-anticoagulation during the initiation phase of therapy. Recent data suggest that polymorphisms in genes encoding several pharmacodynamic determinants of the coagulation cascade may also influence warfarin's antithrombotic dose-response. Of these, VKORC1 polymorphisms account for a significant proportion of the inter-individual variability in warfarin dose requirements in all populations evaluated. Collectively, these data suggest that assessment of genetic polymorphisms affecting both warfarin pharmacokinetics and pharmacodynamics could help to predict warfarin dose requirements in patients. Therefore, the promise of pharmacogenomic-guided dosing as a useful strategy to improve clinical outcomes with warfarin therapy appears credible and warrants further investigation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dumas</LastName>
            <ForeName>Todd E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hawke</LastName>
            <ForeName>Roy L</ForeName>
            <Initials>RL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Craig R</ForeName>
            <Initials>CR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Clin Pharmacol</MedlineTA>
        <NlmUniqueID>101273158</NlmUniqueID>
        <ISSNLinking>1574-8847</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D006899">Mixed Function Oxygenases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.-</RegistryNumber>
          <NameOfSubstance UI="C450260">CYP2C9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.-</RegistryNumber>
          <NameOfSubstance UI="D065729">Cytochrome P-450 CYP2C9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.1</RegistryNumber>
          <NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.17.4.4</RegistryNumber>
          <NameOfSubstance UI="C578523">VKORC1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.17.4.4</RegistryNumber>
          <NameOfSubstance UI="D064417">Vitamin K Epoxide Reductases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065729" MajorTopicYN="N">Cytochrome P-450 CYP2C9</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006899" MajorTopicYN="N">Mixed Function Oxygenases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064417" MajorTopicYN="N">Vitamin K Epoxide Reductases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>95</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18690851</ArticleId>
        <ArticleId IdType="doi">10.2174/157488407779422276</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
